Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubrogepant for acute treatment of migraine during prodrome
NCT04492020Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ubrogepant in migraine, sponsored by AbbVie Inc.. Started Aug 2020; status: completed.
02
Drugs
ubrogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04492020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04492020.